Researcher Profile

Joseph R. Bertino, MD

Chief Scientific Officer; Co-Leader, Cancer Pharmacology and Preclinical Therapeutics Research Program; Director of Pharmacokinetics and Pharmacodynamics Shared Resource at the Rutgers Cancer Institute of New Jersey
University Professor of Medicine and Pharmacology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914

Phone: (732) 235-8510
Email: bertinoj@rutgers.edu

Assistant: Audrea Henry
(732) 235-8520
Email: henryau@cinj.rutgers.edu

Resident Member, Rutgers Cancer Institute of New Jersey


Research Program Alignment

Membership Type: Full


Research Interests

  • Stem Cells
  • Gene Therapy
  • BMT
  • Bmi-1
  • Prostate Cancer
  • Drug resistance
  • Folate antagonists

Selected Publications

Roussel, B, Johnson-Farley, N, Kerrigan JE, Scotto, KW, Banerjee, D, Felczak, K, Pankiewicz, KW, Gounder, M, Lin, H, Abali, EE, Bertino, JR. A second target benzamide riboside. Cancer Biology & Therapy 2012, October 30.

Bertino, JR, Lubin, M, Johnson-Farley, N, Chan, WC, Goodell, L, Bhagavathi, S. Lack of expression of MTAP in uncommon T-cell lymphomas. Clinical Lymphoma, Myeloma & Leukemia, 2012, October 1.

Kerrigan, JE, Abali, EE, Bertino, JR. Recent progress in Molecular dynamics simulations of Dihydrofolate Reductase. Current Enzyme Inhibition. 2012, September 1.

Abali, EE, Celikkaya, H, Hsieh, Y-C, Banerjee, D, Bertino, JR. Novel therapeutic approaches to regulate human dihydrofolate reductase activity and expression. Current Enzyme Inhibition, 2012, August 30.

Budak-Alpdogan, T, Jeganathan, G, Lee, K.C, Mrowiec, Z.R, Medina, D.J, Todd,,D, Moore, D., Bertino, J.R, Strair, R.Irridated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice. Bone Marrow Transplant, 2012, May 21.

Gounder, M.K., Bertino, J.R., Kong, A.N., Dipaola, R.S, Stein, M.N. A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinectic studies. J. Pharm. Biomed Anal. Mar 24; Epub 2012.

Collins, C.C., Stanislav, V., Volik, A., Lapuk, Wang Y, Gout, P.W., Wu, C., Xue, H., Cheng,   H., Haegert, A., Bell, R.H., Brahmbhatt, S., Anderson, S., Fazli, L., Hurtado-Coll, A., Rubin, M.A., Demichelis, F., Beltran, H., Hirst, M., Marra, M.A., Maher, C.A., Chinnaiyan, A.M., Gleave, M.E., Bertino, J.R., Lubin, M., Wang, Y. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target, Mol. Cancer Ther. 2012, March; 11(3):775-83 Epub 2012, Jan17.

Barboza, N.M., Medina, D.J., Budak-Alpdogan,T., Aracil, M., Jimeno, J.M., Bertino, J.R., Banerjee, D. Plitepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol. Ther. 2012, Jan 15 13(2):114-22.

Kamen, B.A., Bertino, J.R., Holcenberg, J.S., Bleyer, W.A.  Are we getting closer to using methotrexate in an optimal manner? J Clin Oncol. 2011, Sep 1;29(25):3493-4.  Aug 1.

Bertino,J.R., Waud,W.R., Parker,W.B., Lubin, M: Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity current strategies. Cancer Biology & Therapy 11:7 2011, Apr. 1.

Moroz, M.A., Kochetkov, T., Cai, S., Wu, J., Shamis, M., Nair, J.S, de Stanchina, E., Serganova I, Schwartz, G.K., Banerjee, D., Bertino, J.R., Blasberg, R. Imaging colon cancer response following treatment with AZD 1152: a pre-clinical analysis of 18 fluoro-2-deoxyglucose and3'-deoxy-3'- 18 fluorothymidine imaging. Clin Cancer Res. 2011, Jan. 18.

Peters, R., Wolf, M.J., van den Broek, M., Nuvolone, M., Dannenmann, S., Stieger, B., Rapold, R., Konrad, D., Rubin, A., Bertino, J.R., Aguzzi, A., Heikenwalder, M., Knuth, A.K:  Efficient  generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma free liquid culture. PLoS One, 2010, Dec 30;5 (12):e15689.

Budak-Alpdogan, T., Bertino, J.R. Chemoprotection by transfer of resistance genes.Methods Mol biol 2009:542;661-704.

Mishra, P.J., Song, B., Mishra, P.J., Wang, Y., Humeniuk, R., Banerjee, D., Merlino, G., Ju, J., Bertino, J.R. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One. 2009, Dec. 24; 4(12):e8445.

Bertino, J.R. Cancer research: from folate antagonism to molecular targets. Best Practice Res Clin. Hematology, 2009, Dec 22; (4):577-82.

The content for this Research Profile is maintained by Paul Novembre (novembre@cinj.rutgers.edu)